Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MDMX, also known as MDM4, is a critical negative regulator of the tumor suppressor protein p53. It inhibits p53's transcriptional activity by binding to its transactivation domain. While lacking intrinsic E3 ubiquitin ligase activity, it forms a heterodimer with MDM2 to suppress p53 activity. Overexpression of MDMX is implicated in various cancers, making it a target for therapeutic intervention aimed at restoring wild-type p53 function.
Disrupting the MDMX-p53 interaction, blocking MDMX-MDM2 heterodimerization
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mouse double minute X (MDMX).